Menu Search
Equities

AFT Pharmaceuticals Ltd

AFT:NZC

AFT Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NZD)2.85
  • Today's Change0.01 / 0.35%
  • Shares traded24.89k
  • 1 Year change-16.18%
  • Beta0.6199
Data delayed at least 20 minutes, as of May 17 2024 05:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NZDIncome statement in NZDView more

Year on year AFT Pharmaceuticals Ltd's net income fell -46.32% from 19.85m to 10.65m despite revenues that grew 20.20% from 130.31m to 156.64m. An increase in the selling, general and administrative costs as a percentage of sales from 27.51% to 29.85% was a component in the falling net income despite rising revenues.
Gross margin45.98%
Net profit margin6.31%
Operating margin11.15%
Return on assets7.73%
Return on equity16.65%
Return on investment12.48%
More ▼

Cash flow in NZDView more

In 2023, cash reserves at AFT Pharmaceuticals Ltd fell by 4.65m. However, the company earned 11.63m from its operations for a Cash Flow Margin of 7.42%. In addition the company used 9.18m on investing activities and also paid 6.98m in financing cash flows.
Cash flow per share0.1199
Price/Cash flow per share22.69
Book value per share0.7048
Tangible book value per share0.2307
More ▼

Balance sheet in NZDView more

AFT Pharmaceuticals Ltd has a Debt to Total Capital ratio of 35.66%, a higher figure than the previous year's 13.00%.
Current ratio1.97
Quick ratio0.8372
Total debt/total equity0.5541
Total debt/total capital0.3566
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.